Asthma. Asthma, unspecified
Conditions
Interventions
Intervention 1: 31 patients were selected as intervention group and treat with atorvastatin tablets (by: Sobhan Pharmaceutical Company) 40 milligram daily for 8 weeks . At the begining of the study a
also a peripheral blood sample is taken to measure blood eosinophil counts and patients’ serum low density lipoprotein-cholesterol(LDL-C), low density lipoprotein-cholesterol (HDL-C), total cholestero
Treatment - Drugs
31 patients were selected as intervention group and treat with atorvastatin tablets (by: Sobhan Pharmaceutical Company) 40 milligram daily for 8 weeks . At the begining of the study after obtaining f
31 patients were selected as Control group and receive placebo daily for 8 weeks . At the begining of the study after obtaining formal consent, the standard questionnaire of asthma control test (ACT)
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria included: patients with mild persistent to moderate persistent asthma (grade 2 and 3 criteria, the severity of asthma), age 18 to 70 years and acceptance of written consent. Exclusion criteria included: pregnancy, people who currently are taking statin drugs , history of sensitivity to statin drugs, History of hospitalization during a month before the research, smokers, history of hepatitis or active liver disease ,myopathy or myositis
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expected primary outcome was improvement in the degree of clinical control of asthma symptoms [base on standardized Asthma Control Test (ACT)]. Timepoint: At the onset of the study and 8 week after treatment with atorvastatin. Method of measurement: base on standardized Asthma Control Test (ACT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes included lung volumes [percent of forced expiratory volume in one second (FEV1 %) and percent of forced vital capacity (FVC%)] and reduction of the number of peripheral blood eosinophils. Timepoint: At the onset of the study and 8 week after treatment with atorvastatin. Method of measurement: spirometry and peripheral blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Abdollatif Moini
Arak University of Medical Sciences
Outcome results
None listed